Madrigal Pharmaceuticals (MDGL) Enterprise Value (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Enterprise Value for 17 consecutive years, with -$838.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Enterprise Value fell 5.24% year-over-year to -$838.8 million; the TTM figure through Jun 2026 stood at -$838.8 million (down 5.24% YoY), while the FY2025 annual figure was -$983.6 million, down 6.19% from the prior year.
• Enterprise Value slipped to -$838.8 million in Q2 2026 per MDGL's latest filing, from -$812.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$153.2 million in Q3 2022 and bottomed at -$1.1 billion in Q3 2025.
• Historically, Enterprise Value has averaged -$659.2 million across 5 years, with a median of -$804.9 million in 2025.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 48.79% — and 2024, when it slumped 329.79%.
• Madrigal Pharmaceuticals' Enterprise Value stood at -$358.8 million in 2022, then sank by 76.75% to -$634.1 million in 2023, then slumped by 46.07% to -$926.3 million in 2024, then declined by 6.19% to -$983.6 million in 2025, then increased by 14.72% to -$838.8 million in 2026.
• Business Quant data shows MDGL's Enterprise Value at -$838.8 million in Q2 2026, -$812.8 million in Q1 2026, and -$983.6 million in Q4 2025.